Shanghai Medicilon Inc.
Shanghai Medicilon Inc., often referred to simply as Medicilon, is a leading contract research organisation (CRO) headquartered in Shanghai, China. Established in 2004, the company has rapidly expanded its operational footprint across major regions, including North America and Europe, positioning itself as a key player in the pharmaceutical and biotechnology sectors. Medicilon offers a comprehensive suite of services, including drug discovery, preclinical development, and laboratory services, distinguished by its commitment to quality and innovation. The company has achieved significant milestones, such as the successful completion of numerous projects that have advanced drug development for various therapeutic areas. With a strong market presence and a reputation for excellence, Shanghai Medicilon Inc. continues to support clients in navigating the complexities of drug development, making it a trusted partner in the life sciences industry.
DitchCarbon Score
How does Shanghai Medicilon Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Shanghai Medicilon Inc.'s score of 20 is lower than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Shanghai Medicilon Inc.'s reported carbon emissions
Shanghai Medicilon Inc., headquartered in CN, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Shanghai Medicilon may not have established formal commitments to reduce its carbon footprint or engage in industry-standard climate initiatives such as the Science Based Targets initiative (SBTi) or the Carbon Disclosure Project (CDP). As a result, the company's climate commitments remain unclear, and it appears to be operating without a defined strategy for addressing carbon emissions or sustainability within its operations.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Shanghai Medicilon Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
